Radiation Dose Escalation Study for Advanced Liver Cancer
NCT00848094 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2009-02-20
Summary
The purpose of this clinical study is to determine the maximum tolerated dose (MTD) of 3-dimensional conformal radiation therapy (3-DCRT)/intensity modulated radiation therapy (IMRT) for locally advanced hepatocellular carcinoma (HCC).
Conditions
Interventions
- RADIATION
-
3DCRT/IMRT
The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
- RADIATION
-
3DCRT/IMRT
The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Guoliang Jiang, M.D. · Fudan University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-04-30
- Primary Completion
- 2008-01-31
- Completion
- 2008-05-31
More Related Trials
-
The Efficacy of Sequential RT After Triple Therapy for uHCC
NCT07052448 ·Status: ENROLLING_BY_INVITATION
-
Dose Escalation Study for Primary Hepatocellular Carcinoma
NCT00243841 ·Status: COMPLETED ·Phase: NA
-
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
NCT05738447 ·Status: UNKNOWN ·Phase: PHASE1
-
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
NCT02578602 ·Status: COMPLETED ·Phase: PHASE1
-
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
NCT00093444 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
NCT04329429 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
NCT05718492 ·Status: RECRUITING ·Phase: NA
-
Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma
NCT03535259 ·Status: COMPLETED ·Phase: PHASE2
-
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
NCT05311319 ·Status: UNKNOWN ·Phase: PHASE2
-
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
NCT04299581 ·Status: RECRUITING ·Phase: PHASE2
-
Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma
NCT00216437 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
NCT02513199 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy
NCT00482586 ·Status: COMPLETED
-
Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
NCT03672305 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
NCT05791448 ·Status: RECRUITING ·Phase: PHASE1
-
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
NCT00999843 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma
NCT01668134 ·Status: COMPLETED ·Phase: PHASE1
-
Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
NCT00557024 ·Status: UNKNOWN ·Phase: PHASE4
-
Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma(AICRC)
NCT06997913 ·Status: ENROLLING_BY_INVITATION
-
Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma
NCT06966986 ·Status: ACTIVE_NOT_RECRUITING
-
Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC
NCT04791176 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
NCT04444167 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
NCT05660213 ·Status: NOT_YET_RECRUITING
-
Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
NCT01194206 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
NCT04152356 ·Status: UNKNOWN